Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 17% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (136 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: equal togreaterbowelpainibs
  Phrases that lowered it: foodinvestigatestudyeffectdose
• Primary purpose: not given (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 9.7% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Responsible party: not given (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 117 (lowers risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Maximum age: 75 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 19.6% (lowers risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Sponsor's past trials: 195 (lowers risk) · Sponsor's track record
• Collaborators: 2 (lowers risk) · Design
• Drug's FAERS reports marked serious: 90.8% (raises risk) · Drug's FDA history
• Keywords listed: 6 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome NCT01786109 · started 2009 · scored riskier than 71% of active trials completed
• Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome NCT04655599 · started 2021 · scored riskier than 11% of active trials terminated
• Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS) NCT01327300 · started 2010 · scored riskier than 42% of active trials completed
• A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) NCT01870895 · started 2013 · scored riskier than 10% of active trials completed
• Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome NCT03806127 · started 2018 · scored riskier than 69% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.